Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$21.1M Buy
83,772
+8,862
+12% +$1.91M 0.22% 50
2026
Q1
$16.3M Sell
74,910
-22,335
-23% -$4.95M 0.18% 59
2025
Q4
$22.2M Buy
97,245
+2,596
+3% +$591K 0.29% 42
2025
Q3
$21.9M Sell
94,649
-402
-0.4% -$81.9K 0.47% 35
2025
Q2
$17.6M Sell
95,051
-2,392
-2% -$445K 0.42% 45
2025
Q1
$20.4M Buy
97,443
+1,883
+2% +$366K 0.54% 31
2024
Q4
$16.8M Sell
95,560
-5,611
-6% -$1.03M 0.44% 44
2024
Q3
$20M Buy
101,171
+21,658
+27% +$4.04M 0.54% 35
2024
Q2
$13.6M Sell
79,513
-3,903
-5% -$647K 0.4% 44
2024
Q1
$15.2M Buy
+83,416
New +$14.4M 0.48% 40

Other funds holding ABBV

Allianz's ABBV Position: Q2 2026 in Review

Allianz increased its AbbVie (ABBV) stake by 12% in Q2 2026, buying an estimated $1.91M and bringing the position to 83,772 shares worth $21.1M. The position accounts for 0.22% of the portfolio, ranked #50.

Allianz first reported a position in ABBV in Q1 2024 and has held it in 10 quarters since. The position peaked at $22.2M in Q4 2025. 4,209 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Allianz held 83,772 shares of AbbVie worth $21.1M as of Q2 2026.
  • Allianz bought 8,862 AbbVie shares in Q2 2026, an estimated $1.91M.
  • AbbVie made up 0.22% of Allianz's portfolio in Q2 2026, its #50 holding.
  • Allianz first reported a position in AbbVie in Q1 2024 and has held it in 10 quarters since.
  • Allianz's AbbVie position peaked at $22.2M in Q4 2025.
  • 4,209 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Allianz's 13F filing for Q2 2026, filed 10 Aug 2026.